Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Reactogenicity of Fluarix/Influsplit 2013/2014 in Adults
NCT01884519Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2013
- Primary completion
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Fluarix in influenza (2 arms), sponsored by GSK. Primary endpoints: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers at Day 21, Number of Subjects Who Were Seroprotected for Anti-HI Antibodies at Day 21 and 3 more. Started Jul 2013; status: completed.
02
Drugs
Fluarix
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01884519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884519.